| | |  | | | | Record from Web of Science® | | | | | | |
| Anthracycline antibiotics non-covalently incorporated into the block copolymer micelles: In vivo evaluation of anti-cancer activity |
|
|
| Author(s): Batrakova EV, Dorodnych TY, Klinskii EY, Kliushnenkova EN, Shemchukova OB, Goncharova ON, Arjakov SA, Alakhov VY, Kabanov AV |
| Source: BRITISH JOURNAL OF CANCER Volume: 74 Issue: 10 Pages: 1545-1552 Published: NOV 1996 |
| Times Cited: 76 References: 27 |
| Abstract: The chemosensitising effects of poly(ethylene oxide)-poly(propylene oxide)-poly-(ethylene oxide) (PEO-PPO-PEO) block copolymers (pluronic) in multidrug-resistant cancer cells has been described recently (Alakhov VY, Moskaleva EY, Batrakova EV, Kabanov AV 1996, Biocon. Chem., 7, 209). This paper presents initial studies on in vivo evaluation of Pluronic copolymers in the treatment of cancer. The anti-tumour activity of epirubicin (EPI) and doxorubicin (DOX), solubilised in micelles of Pluronic L61, P85 and F108, was investigated using murine leukaemia P388 and daunorubicin-sensitive Sp2/0 and -resistant Sp2/0(DNR) myeloma cells grown subcutaneously (s.c.). The study revealed that the lifespan of the animals and inhibition of tumour growth were considerably increased in mice treated with drug/copolymer compositions compared with animals treated with the free drugs. The anti-tumour activity of the drug/copolymer compositions depends on the concentration of the copolymer and its hydrophobicity, as determined by the ratio of the lengths of hydrophilic PEO and hydrophobic PPO segments. The data suggest that higher activity is associated with more hydrophobic copolymers. In particular, a significant increase in lifespan (T/C>150%) and tumour growth inhibition (>90%) was observed in animals with Sp2/0 tumours with EPI/P85 and DOX/L61 compositions. The effective doses of these compositions caused inhibition of Sp2/0 tumour growth and complete disappearance of tumour in 33-50% of animals. Future studies will focus on the evaluation of the activity of Pluronic-based compositions against human drug-resistant tumours. |
| Document Type: Article |
| Language: English |
Addresses:
1. MOSCOW INST BIOTECHNOL INC, MOSCOW 113149, RUSSIA
2. RUSSIAN RES CTR MOL DIAGNOST & THERAPY, MOSCOW 113149, RUSSIA
3. MOSCOW MV LOMONOSOV STATE UNIV, FAC CHEM, DEPT POLYMER SCI, MOSCOW 119899, RUSSIA |
| Publisher: STOCKTON PRESS, HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS |
| Subject Category: Oncology |
| IDS Number: VR947 |
| ISSN: 0007-0920 |
|
| | | | | | | | | Record from Web of Science® | | | | | | | | | |